Arrowhead Pharmaceuticals shares are higher in Tuesday trading after Morgan Stanley upgraded the stock to Overweight in a pre-market note dated April 21, 2026. The upgrade acted as the key near-term catalyst, driving renewed attention to Arrowhead’s risk/reward profile following a volatile period for biotech and company-specific swings tied to pipeline updates and funding activity.

An upgrade from a large sell-side firm can meaningfully shift near-term flows in a single-name biotech, particularly when the company is approaching pivotal clinical and commercial milestones. For Arrowhead, the market is focused on execution into 2026—both on progressing late-stage programs and translating its first marketed product into early commercial traction—so a more constructive stance from a major bank can compress perceived financing and pipeline risk.

After the initial upgrade-driven pop, follow-through will likely depend on upcoming clinical and regulatory milestones across Arrowhead’s RNAi platform and any incremental evidence that the commercial build is converting into durable demand. Investors will also monitor cash and capital strategy given Arrowhead’s recent use of equity and convertible financing, since future dilution expectations can quickly influence biotech multiples.